A new Review published in Ferroptosis and Oxidative Stress (FOS) explores whether a single class of molecules could simultaneously inhibit two interconnected forms of regulated cell death-necroptosis and ferroptosis-potentially opening new directions for therapeutic research.
Necroptosis and ferroptosis are distinct forms of regulated cell death, but growing evidence suggests that the two pathways can intersect through cellular stress responses, lipid metabolism, redox regulation, and inflammatory signaling. This crosstalk raises an important question: Could targeting both pathways simultaneously provide advantages over inhibiting either pathway alone?
In the Review "NecroFerrins as dual therapeutic inhibitors targeting necroptosis and ferroptosis" authors Claire Delehouzé and Stéphane Bach examine the emerging concept of molecules capable of simultaneously interfering with these two cell-death pathways. The authors refer to these dual-action compounds as "NecroFerrins" and discuss their potential implications for multi-target strategies against regulated cell death.
Why Target Two Cell-Death Pathways?
Necroptosis and ferroptosis are regulated through distinct molecular mechanisms. Necroptosis is primarily associated with the RIPK1–RIPK3–MLKL signaling pathway, whereas ferroptosis is driven by iron-dependent lipid peroxidation.
However, cells do not necessarily activate these pathways in isolation. Depending on the cellular context, metabolic state, and type of stress, multiple forms of regulated cell death may be engaged or compensate for one another. This interconnectedness may limit the effectiveness of strategies that target only one pathway.
The Review therefore explores an alternative pharmacological concept: using a single molecule to interfere with multiple interconnected cell-death mechanisms.
Introducing "NecroFerrins"
The authors use the term NecroFerrins to describe molecules with dual inhibitory activity against necroptosis and ferroptosis. Rather than targeting a single protein within one pathway, these compounds may act across interconnected mechanisms of regulated necrosis.
One important example discussed in the Review is RIPROStatins, a class of compounds that combine inhibition of RIPK1-dependent necroptosis with radical-trapping antioxidant activity. This dual activity brings together suppression of necroptotic signaling through RIPK1 and inhibition of lipid radical propagation associated with ferroptotic damage.
Beyond Single-Target Drug Discovery
The concept of NecroFerrins reflects a broader shift toward polypharmacology, in which a single compound can influence multiple biologically connected targets or pathways.
For diseases involving complex and overlapping mechanisms of tissue injury, simultaneously modulating necroptosis and ferroptosis could potentially provide a broader approach to regulating pathological cell death. At the same time, the therapeutic development of such compounds will require careful evaluation of their molecular targets, specificity, pharmacological properties, and effects in different disease contexts.
The authors highlight these challenges while discussing how advances in chemical biology and regulated cell-death research may help identify and optimize compounds capable of controlling multiple cell-death pathways.
A New Perspective on Regulated Cell Death
The emerging concept of NecroFerrins underscores a broader principle in cell-death research: necroptosis and ferroptosis may be better understood as interconnected components of a larger regulated cell-death network rather than completely independent pathways.
By bringing together evidence from necroptosis, ferroptosis, redox biology, and pharmacology, the Review provides a framework for exploring whether dual-pathway inhibition could become a useful strategy for future therapeutic development.
Further research will be needed to determine the therapeutic applicability of NecroFerrins and how effectively these compounds can modulate interconnected cell-death pathways in disease models.
Nevertheless, the concept offers a new way to think about regulated cell death—not simply by asking how to block one pathway, but whether multiple pathways can be controlled simultaneously by a single therapeutic molecule.
